/RYTM
RYTM Stock - Rhythm Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$112.14+0.37%
+$0.41 (+0.37%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.91
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).97
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.41
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+23.5%upside
Target: $138.49
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RYTM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$111.02 – $113.26
TARGET (TP)$138.50
STOP LOSS$103.17
RISK/REWARD1:2.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.97
52W High$122.20
52W Low$45.91
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $130.13M | $77.43M | $23.64M | $3.15M | N/A |
| Gross Profit | $116.76M | $68.13M | $21.50M | $2.56M | $-690,000 |
| Gross Margin | 89.7% | 88.0% | 91.0% | 81.0% | N/A |
| Operating Income | $-265,503,000 | $-184,357,000 | $-179,157,000 | $-170,059,000 | $-136,575,000 |
| Net Income | $-260,602,000 | $-184,678,000 | $-181,119,000 | $-69,612,000 | $-130,727,000 |
| Net Margin | -200.3% | -238.5% | -766.2% | -2207.1% | N/A |
| EPS | $-4.34 | $-3.20 | $-3.51 | $-1.37 | $-2.96 |
Company Overview
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
14
88%
Hold / Neutral
2
13%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
14 Bullish2 Neutral/Bearish
Price Targets
$63
Average Target
↓ 44.1% Downside
Now
$20
Low
$63
Average
$136
High
Based on 17 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 25th 2025 | Citigroup | Initiation | Buy | $136 |
| November 5th 2025 | Oppenheimer | Downgrade | Perform | - |
| July 10th 2025 | Goldman | Initiation | Buy | $97 |
| July 7th 2025 | Leerink Partners | Initiation | Outperform | $88 |
| April 7th 2025 | BofA Securities | Upgrade | Buy | $63 |
| March 5th 2025 | Stifel | Resumed | Buy | $78 |
| January 2nd 2025 | Jefferies | Initiation | Buy | $80 |
| December 20th 2024 | Oppenheimer | Initiation | Outperform | $76 |
| October 21st 2024 | Guggenheim | Initiation | Buy | $70 |
| September 18th 2024 | H.C. Wainwright | Initiation | Buy | $64 |
| September 17th 2024 | JMP Securities | Initiation | Mkt Outperform | $64 |
| May 8th 2024 | BofA Securities | Downgrade | Neutral | $42← $49 |
| December 19th 2023 | Morgan Stanley | Upgrade | Overweight | $55← $29 |
| August 1st 2023 | BofA Securities | Upgrade | Buy | $27← $22 |
| January 18th 2023 | Canaccord Genuity | Resumed | Buy | $52 |
Earnings History & Surprises
RYTMBeat Rate
39%
Last 18 quarters
Avg Surprise
-0.2%
EPS vs Estimate
Beats / Misses
7/9
2 met exactly
Latest EPS
$-0.82
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.70vs$-0.70
Q2 24
-0.4%
$-2.35vs$-2.34
Q3 24
+21.4%
$-0.55vs$-0.70
Q4 24
+8.8%
$-0.73vs$-0.80
Q1 25
-4.3%
$-0.72vs$-0.69
Q2 25
-17.4%
$-0.81vs$-0.69
Q3 25
-13.6%
$-0.75vs$-0.66
Q4 25
-13.9%
$-0.82vs$-0.72
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.79 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.72 | $-0.82 | -13.9% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.66 | $-0.75 | -13.6% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.69 | $-0.81 | -17.4% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.69 | $-0.72 | -4.3% | ✗ MISS |
Q4 2024 | Nov 5, 2024 | $-0.80 | $-0.73 | +8.8% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.70 | $-0.55 | +21.4% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-2.34 | $-2.35 | -0.4% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $-0.70 | $-0.70 | 0.0% | = MET |
Q4 2023 | Nov 7, 2023 | $-0.76 | $-0.76 | 0.0% | = MET |
Q3 2023 | Aug 1, 2023 | $-0.80 | $-0.82 | -2.5% | ✗ MISS |
Q2 2023 | May 2, 2023 | $-0.71 | $-0.92 | -29.6% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-0.82 | $-0.75 | +8.5% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-1.01 | $-0.79 | +21.8% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.79 | $-0.89 | -12.7% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-0.98 | $-1.05 | -7.1% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-1.00 | $-0.85 | +15.0% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-0.84 | $-0.70 | +16.7% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-0.75 | $-0.70 | +6.7% | ✓ BEAT |
Latest News
Guggenheim Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $140
📈 PositiveBenzinga•Dec 17, 2025, 12:54 PM
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $141
📈 PositiveBenzinga•Dec 12, 2025, 06:14 PM•Also:
Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $157
📈 PositiveBenzinga•Dec 12, 2025, 05:56 PM
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $167
📈 PositiveBenzinga•Dec 12, 2025, 01:14 PM
Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $145
📈 PositiveBenzinga•Dec 11, 2025, 06:45 PM
Rhythm advances lead asset into late-stage trial in Prader-Willi syndrome
📈 PositiveSeeking Alpha•Dec 11, 2025, 05:23 PM
Rhythm Pharmaceuticals shares are trading higher after the company announced preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome.
📈 PositiveBenzinga•Dec 11, 2025, 03:48 PM
Rhythm Pharma Announces Preliminary Results From Exploratory Phase 2 Trial Of Setmelanotide In Patients With Prader-Willi Syndrome
➖ NeutralBenzinga•Dec 11, 2025, 12:33 PM
Rhythm Pharmaceuticals To Unveil Preliminary Phase 2 Data For Setmelanotide In Prader–Willi Syndrome On December 11 At 8:00am ET
📈 PositiveBenzinga•Dec 10, 2025, 09:02 PM
Citigroup Initiates Coverage On Rhythm Pharmaceuticals with Buy Rating, Announces Price Target of $136
📈 PositiveBenzinga•Nov 25, 2025, 02:16 PM•Also:
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $114
📈 PositiveBenzinga•Nov 10, 2025, 08:36 PM•Also:
Rhythm Pharmaceuticals Data From Phase 3 TRANSCEND Study Demonstrates Significant BMI Reductions In Participants With Acquired Hypothalamic Obesity On Concomitant Treatment With Glp-1 Therapy
📈 PositiveBenzinga•Nov 10, 2025, 12:14 PM
Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $120
📈 PositiveBenzinga•Nov 7, 2025, 07:45 PM
Rhythm Pharmaceuticals Announces FDA Extension Of Review Period For IMCIVREE From Dec. 20 To Mar. 20
➖ NeutralBenzinga•Nov 7, 2025, 12:31 PM
Rhythm Pharmaceuticals Signs Agreements With Five Canadian Provinces, Federal Non-Insured Health Benefits Program For Public Reimbursement Of IMCIVREE For Weight Management
📈 PositiveBenzinga•Nov 5, 2025, 09:15 PM
Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $122
📈 PositiveBenzinga•Nov 4, 2025, 05:06 PM
Rhythm Pharmaceuticals Q3 EPS $(0.82) Misses $(0.73) Estimate, Sales $51.298M Beat $50.705M Estimate
➖ NeutralBenzinga•Nov 4, 2025, 12:00 PM
Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $139
➖ NeutralBenzinga•Oct 17, 2025, 05:21 PM
Morgan Stanley Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $129
📈 PositiveBenzinga•Oct 16, 2025, 06:01 PM
HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $110
📈 PositiveBenzinga•Sep 29, 2025, 10:31 AM
Frequently Asked Questions about RYTM
What is RYTM's current stock price?
Rhythm Pharmaceuticals, Inc. (RYTM) is currently trading at $112.14 per share. The stock has moved +0.37% today.
What is the analyst price target for RYTM?
The average analyst price target for RYTM is $138.50, based on 1 analyst.
What sector is Rhythm Pharmaceuticals, Inc. in?
Rhythm Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RYTM's market cap?
Rhythm Pharmaceuticals, Inc. has a market capitalization of $7.48 billion, making it a mid-cap company.
Does RYTM pay dividends?
No, Rhythm Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
AKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
ARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
BDTX
Black Diamond Therapeutics, Inc.
$2.54
Mkt Cap: $0.1B
CGEM
Cullinan Therapeutics, Inc.
$9.68
Mkt Cap: $0.6B
INZY
Inozyme Pharma, Inc.
$4.00
Mkt Cap: $0.3B
KNSA
Kiniksa Pharmaceuticals, Ltd.
$43.19
Mkt Cap: $3.2B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
NUVL
Nuvalent, Inc.
$103.80
Mkt Cap: $7.5B
PLRX
Pliant Therapeutics, Inc.
$1.23
Mkt Cap: $0.1B
Explore stocks similar to RYTM for comparison